section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF, peripheral edema ( with thiazolidinediones).

Derm: bullous pemphigoid.

Endo: hypoglycemia ( with sulfonylureas).

GI: abdominal pain, PANCREATITIS, vomiting.

Hemat: lymphocyte count.

MS: arthralgia, RHABDOMYOLYSIS.

Neuro: headache.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

Renal Impairment

US Brand Names

Onglyza

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification:

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4/5 isoenzyme, with conversion to 5-hydroxysaxagliptin, a pharmacologically active metabolite; 24% of saxagliptin is excreted unchanged in urine, 36% of hydroxysaxagliptin is excreted unchanged in urine, 22% is eliminated in feces as unabsorbed drug/metabolites excreted in bile.

Half-life: Saxagliptin: 2.5 hr; 5-hydroxysaxagliptin: 3.1 hr.

Time/Action Profile

(DPP-4 inhibition)

ROUTEONSETPEAKDURATION
POunknown2 hr (4 hr for 5-hydroxysaxagliptin)24 hr

†Blood levels.

Patient/Family Teaching

Pronunciation

sax-a-GLIP-tin